Introduction
Understanding Timelines for IND submission and review is essential for B. Pharm students preparing for roles in clinical development and regulatory affairs. This concise guide covers key timelines—initial 30-day FDA safety review, PDUFA goals, priority vs standard review, clinical holds, pre-IND meetings, IND amendments, safety reporting deadlines, eCTD/CTD filing structure, CMC and preclinical data requirements, and expedited pathways like Fast Track and Breakthrough. By focusing on regulatory milestones, required documents, and common sponsor responses, students will gain practical insight into IND workflow and decision points. Keywords: IND submission timelines, 30-day review, clinical hold, adverse event reporting, pre-IND. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What does IND stand for in regulatory submissions?
- Investigational New Drug application
- International New Drug dossier
- Initial New Development report
- Investigational New Device application
Correct Answer: Investigational New Drug application
Q2. What is the usual FDA initial review period for a new IND submission?
- 7 days
- 15 days
- 30 days
- 90 days
Correct Answer: 30 days
Q3. If the FDA does not place a clinical hold within the initial review period, what happens?
- The IND is denied
- The IND becomes effective and the sponsor may proceed with clinical trials
- The sponsor must wait another 60 days
- The FDA issues a conditional approval letter
Correct Answer: The IND becomes effective and the sponsor may proceed with clinical trials
Q4. What is a clinical hold?
- An FDA request to speed up trials
- An FDA decision to stop or delay a proposed clinical investigation
- A sponsor’s suspension of manufacturing
- A requirement to submit more batches
Correct Answer: An FDA decision to stop or delay a proposed clinical investigation
Q5. What is the main purpose of a pre-IND meeting?
- To request marketing approval
- To discuss development plans and data expectations with FDA before IND submission
- To file the final clinical study report
- To submit the eCTD gateway application
Correct Answer: To discuss development plans and data expectations with FDA before IND submission
Q6. What does eIND refer to?
- Electronic IND submission only for Europe
- Emergency Investigational New Drug application
- Enhanced IND review pathway
- Enterprise IND tracking system
Correct Answer: Emergency Investigational New Drug application
Q7. Which expedited designation commonly allows rolling submission of modules to FDA?
- Fast Track designation
- Orphan Drug designation
- Standard Review
- Pediatric exclusivity
Correct Answer: Fast Track designation
Q8. Under PDUFA, what is the target review time for a standard NDA/BLA?
- 2 months
- 6 months
- 10 months
- 18 months
Correct Answer: 10 months
Q9. What is the PDUFA target review time for a priority NDA/BLA?
- 1 month
- 6 months
- 10 months
- 15 months
Correct Answer: 6 months
Q10. FDA can impose what types of clinical hold?
- Only full holds
- Only informal holds
- Partial or full clinical holds
- Administrative holds that do not affect trials
Correct Answer: Partial or full clinical holds
Q11. Which submission is required when a sponsor plans a significant change in a protocol that increases risk?
- Annual report
- Protocol amendment
- New drug application
- Investigator brochure update only
Correct Answer: Protocol amendment
Q12. Who submits an Investigator IND?
- The pharmaceutical company only
- The clinical investigator who both initiates and conducts the trial
- The FDA on behalf of the investigator
- A contract research organization exclusively
Correct Answer: The clinical investigator who both initiates and conducts the trial
Q13. How often must a sponsor submit an annual IND safety report to FDA?
- Monthly
- Quarterly
- Annually
- Only at trial completion
Correct Answer: Annually
Q14. What does eCTD stand for?
- electronic Clinical Trial Database
- electronic Common Technical Document
- enhanced Clinical Trial Dossier
- electronic Chemical Technical Data
Correct Answer: electronic Common Technical Document
Q15. In the CTD structure, which module contains CMC (chemistry, manufacturing, controls) information?
- Module 1
- Module 2
- Module 3
- Module 5
Correct Answer: Module 3
Q16. Which preclinical studies are typically required to support first‑in‑human IND entry?
- Single in vitro assay only
- Repeat‑dose toxicity studies in two species plus safety pharmacology and genotoxicity as appropriate
- Marketing authorization studies
- Only human volunteer studies
Correct Answer: Repeat‑dose toxicity studies in two species plus safety pharmacology and genotoxicity as appropriate
Q17. Investigators should report life‑threatening or fatal suspected adverse reactions to the sponsor within what timeframe?
- 24 hours
- 7 days
- 30 days
- Annually
Correct Answer: 24 hours
Q18. When can the FDA impose a clinical hold on an IND?
- Only after phase 3 begins
- Anytime, including during the initial 30‑day review period
- Only during marketing review
- Only if the sponsor requests it
Correct Answer: Anytime, including during the initial 30‑day review period
Q19. Which of the following is a key benefit of Fast Track designation regarding timelines?
- Guaranteed approval within 3 months
- Ability to request rolling review of sections prior to complete submission
- Exemption from preclinical testing
- Extended exclusivity without approval
Correct Answer: Ability to request rolling review of sections prior to complete submission
Q20. Which regulatory pathway can allow use of an unapproved product in a public health emergency without an IND?
- Breakthrough Therapy designation
- Emergency Use Authorization (EUA)
- Priority Review
- Orphan Drug status
Correct Answer: Emergency Use Authorization (EUA)
Q21. The FDA’s 30‑day IND safety review clock starts when?
- When the sponsor sends the first clinical protocol email
- When FDA receives the IND submission
- When the first patient is dosed
- When preclinical studies are complete
Correct Answer: When FDA receives the IND submission
Q22. If an IND is placed on clinical hold, what is the typical sponsor response?
- Ignore the hold and proceed
- Address FDA’s concerns by submitting additional data or protocol modifications and request a meeting if needed
- Withdraw the IND automatically
- File for immediate marketing approval
Correct Answer: Address FDA’s concerns by submitting additional data or protocol modifications and request a meeting if needed
Q23. Fatal or life‑threatening suspected adverse reactions must be reported to FDA within what timeframe?
- 24 hours
- 7 calendar days
- 30 calendar days
- Annually
Correct Answer: 7 calendar days
Q24. Which FDA meeting type is typically used for pre‑IND discussions?
- Type A meeting
- Type B meeting
- Type C meeting
- Type D meeting
Correct Answer: Type B meeting
Q25. In the CTD, which module contains clinical study reports and clinical data?
- Module 1
- Module 3
- Module 4
- Module 5
Correct Answer: Module 5
Q26. If FDA does not issue a clinical hold within the initial review, when may the sponsor begin clinical dosing?
- Immediately after FDA issues an approval letter
- Immediately after the 30‑day review period ends with no hold
- Only after phase 2 protocols are approved
- After 6 months from submission
Correct Answer: Immediately after the 30‑day review period ends with no hold
Q27. When should a sponsor submit an IND amendment for a protocol change that increases subject risk?
- After enrolling all subjects
- Prior to implementing the change unless immediate action is required for subject safety
- Only in the annual report
- Never; changes are allowed without notification
Correct Answer: Prior to implementing the change unless immediate action is required for subject safety
Q28. Which expedited program offers intensive FDA guidance and organizational commitment to accelerate development?
- Standard Review
- Breakthrough Therapy designation
- Orphan Drug designation only
- Patent term extension
Correct Answer: Breakthrough Therapy designation
Q29. What is the principal goal of preclinical pharmacology and toxicology studies before IND filing?
- To obtain marketing exclusivity
- To establish initial safety, pharmacology, and support selection of a starting clinical dose
- To replace clinical trials
- To secure immediate human use without oversight
Correct Answer: To establish initial safety, pharmacology, and support selection of a starting clinical dose
Q30. What does the term “30‑day clock” generally refer to in IND review?
- The time sponsors have to respond to FDA questions
- The FDA’s initial 30‑day safety review period following IND receipt
- Time to complete phase 1 trials
- The grace period before submitting an NDA
Correct Answer: The FDA’s initial 30‑day safety review period following IND receipt
